Moderna, Inc. (MRNA): Price and Financial Metrics


Moderna, Inc. (MRNA): $174.65

6.55 (+3.90%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

Add MRNA to Watchlist
Sign Up

Industry: Biotech


Ranked

of 491

in industry

MRNA Stock Summary

  • MRNA has a higher market value than 96.34% of US stocks; more precisely, its current market capitalization is $67,760,944,149.
  • With a price/sales ratio of 84.34, Moderna Inc has a higher such ratio than 96.03% of stocks in our set.
  • Revenue growth over the past 12 months for Moderna Inc comes in at 1,234.34%, a number that bests 99.36% of the US stocks we're tracking.
  • Stocks with similar financial metrics, market capitalization, and price volatility to Moderna Inc are INCY, GMAB, VIR, RVMD, and MU.
  • Visit MRNA's SEC page to see the company's official filings. To visit the company's web site, go to www.modernatx.com.

MRNA Stock Price Chart Interactive Chart >

Price chart for MRNA

MRNA Price/Volume Stats

Current price $174.65 52-week high $189.26
Prev. close $168.10 52-week low $45.01
Day low $168.35 Volume 6,158,191
Day high $174.94 Avg. volume 11,702,379
50-day MA $147.67 Dividend yield N/A
200-day MA $109.43 Market Cap 69.95B

Moderna, Inc. (MRNA) Company Bio


Moderna, Inc. engages in the development of transformative medicines based on messenger ribonucleic acid (mRNA). Its product pipeline includes the following modalities: prophylactic vaccines, cancer vaccines, intratumoral immuno-oncology, localized regenerative therapeutics, systemic secreted therapeutics, and systemic intracellular therapeutics. The company was founded by Noubar B. Afeyan, Robert S. Langer, Derrick J. Rose, and Kenneth R. Chien in 2010 and is headquartered in Cambridge, MA


MRNA Latest News Stream


Event/Time News Detail
Loading, please wait...

MRNA Latest Social Stream


Loading social stream, please wait...

View Full MRNA Social Stream

Latest MRNA News From Around the Web

Below are the latest news stories about Moderna Inc that investors may wish to consider to help them evaluate MRNA as an investment opportunity.

Pressure mounting on Biden administration to waive COVID-19 vaccine patents

As poorer countries struggle to vaccinate their citizens, calls are growing for the Biden administration to waive COVID-19 patents in a bid to increase vaccine production.Last week, more than 170 former world leaders and Nobel Laureates signed an open letter to President Biden urging him to sign a temporary waiver...

Seeking Alpha | April 21, 2021

OCGN Stock: The Huge COVAXIN News Sending Ocugen Climbing Today

OCGN stock is gaining Wednesday morning on news that Bharat Biotech's COVAXIN has an overall 78% efficacy rate.

Robert Lakin on InvestorPlace | April 21, 2021

The 7 Best-Performing ETFs Money Can Buy In 2021

Here're seven of the most popular ETFs so far in 2021

Tezcan Gecgil on InvestorPlace | April 21, 2021

Most BJP-ruled states announce free jabs for all

Two days after the Centre announced vaccination for all above the age of 18 years from May 1, state governments are busy finalising the modalities to place their orders. While most BJP-ruled states have announced free vaccinations, the worst-affected states like Maharashtra and Delhi are yet to take a call on pricing as well as orders for the vaccine drive.“We have not got any official communication from the Centre on this. We might get this communication by tomorrow and then formulate a plan,” DN Patil, Maharashtra Immunisation officer told ET. Maharashtra has sought the Centre’s nod to import vaccines like Sputnik, Moderna and Pfizer to vaccinate nearly 10 crore of its 12 crore population.Uttar Pradesh health minister Jai Pratap Singh told ET that more clarity needs to emerge on the p...

Economic Times India | April 21, 2021

Why Moderna Stock Jumped Today

Shares of Moderna (NASDAQ: MRNA) were jumping 7.4% higher as of 3:42 p.m. EDT on Wednesday. The gain came after the company announced that it won a new deal to supply its COVID-19 vaccine to Israel for 2022. Moderna didn't reveal how many doses are included in its latest agreement with Israel.

Yahoo | April 21, 2021

Read More 'MRNA' Stories Here

MRNA Price Returns

1-mo 32.70%
3-mo 33.30%
6-mo 147.63%
1-year 268.15%
3-year N/A
5-year N/A
YTD 67.18%
2020 434.10%
2019 28.09%
2018 N/A
2017 N/A
2016 N/A
Page generated in 0.9612 seconds.